Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 08, 2023 at 10:06 pm
Share
Li Kang Biomedical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 126.35 million compared to TWD 185.64 million a year ago. Net income was TWD 19.05 million compared to TWD 31.63 million a year ago. Basic earnings per share from continuing operations was TWD 0.71 compared to TWD 1.18 a year ago. Diluted earnings per share from continuing operations was TWD 0.71 compared to TWD 1.18 a year ago.
For the nine months, sales was TWD 457.63 million compared to TWD 488.85 million a year ago. Net income was TWD 79.99 million compared to TWD 76 million a year ago. Basic earnings per share from continuing operations was TWD 2.98 compared to TWD 2.83 a year ago. Diluted earnings per share from continuing operations was TWD 2.97 compared to TWD 2.82 a year ago.
Li Kang Biomedical Co., Ltd. formerly BAFO TECHNOLOGIES CORP., is engaged in the manufacture and sale of computer, communication and consumer (3C) product cables and circumscribed computer peripheral products, as well as communication products. The Company offers unshielded twisted pair (UTP) cables, monitor cables, small computer system interface (SCSI) cables, universal serial bus (USB) cables, wireless hopping/mesh access points, wireless modules, and wireless vehicle communication systems, among others. The Company distributes its products within the domestic market and to overseas markets, including Europe, the Americas and the rest of Asia.
LI KANG BIOMEDICAL CO., LTD. 
